LATEST NEWS AND EVENTS

News

EANM position paper on the role of radiobiology in nuclear medicine

Aerts, A., Eberlein, U., Holm, S. et al. EANM position paper on the role of radiobiology in nuclear medicine. Eur J Nucl Med Mol...

Events

ANZSNM 2021 Live and Local

Event: 51st Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine (ANZSNM) Date: 21-23 May 2021 This meeting will be moving to...

News

Travel cards could help radiopharma patients avoid delays

April 29, 2020 -- Patients who undergo radiation treatment with lutetium-177 (Lu-177)-DOTATATE for neuroendocrine tumors should receive and carry a travel card with details of...

News

PSMA theranostic Lu-177-PSMA-617 approaches prime time in mCRPC

Urology Times Journal, Jason M. Broderick - April 15, 2021 The PSMA-targeted radiopharmaceutical 177Lu-PSMA-617 (LuPSMA) is rapidly advancing through the pipeline in metastatic castration-resistant prostate...

Events

XXII Congreso Argentino de Medicina Nuclear – Virtual Edition

Event: XXII Congreso Argentino de Medicina Nuclear - Virtual Edition Date: 26-30 April 2021 The Oncidium foundation is proud to be represented by our Ambassadors to...

News

The Noble Registry – An International Collaboration to Develop iPSMA SPECT Imaging for Prostate Cancer

BRUSSELS, Belgium and MELBOURNE, Australia, 20th of April 2021 – The Oncidium foundation, a non-profit organisation created to promote and support the development of...

News

Doctor, What is Neuroendocrine Cancer?

Waiting for a download is frustrating. Imagine waiting 5+ years for a cancer diagnosis. Neuroendocrine cancer takes on average 5+ years to diagnose due...

News

How Nuclear Technology can Beat Cancer

How nuclear medicine can beat cancer? These are extraordinary times, and patients waiting for life-changing medical treatments should not suffer. They want to know...

News

Seeing Cancer Cells, Killing Cancer Cells

Using molecules to safely carry radioactive materials inside the human body is helping physicians get more accurate images of tumors and more effectively eliminate...

News

Evolving role of Ac-225-PSMA Radioligand Therapy in mCRPC

225Ac-PSMA RLT is an efficacious and safe treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC). Future randomized controlled trials are required to...

News

World Theranostics Day 2021!

Today is World Theranostics Day! On this day in 1941, the first radioiodine treatment was administered and we are very eager to see what's...

News

How PRRT can Improve Care for Neuroendocrine Tumor Patients

Learn more about how Peptide Receptor Radionuclide Therapy (PRRT) can improve care for Neuroendocrine Tumor patients. Another effective illustration of how Radiotheranostics work and...

News

Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy

With some radiopharmaceuticals now used in clinical practice, somatostatin analogs developed for imaging and therapy are an example of the concept of personalized medicine...

News

Real-world data analysis of efficacy and survival after Lu-177 PSMA in metastatic castration-resistant prostate cancer

177Lu-PSMA radioligand therapy provides a significant response rate with a low toxicity profile. The evidence promotes greater efficacy of radioligand therapy in predominantly lymph...

News

PSMA Lu-177 x Ac-225

Available since 2015, the treatment of patients with metastatic castration-resistant prostate cancer (mCRPCC) with the beta-emitter Lutetium-177 has had several early-stage dosimetry studies published,...

News

What is in the pipeline for nuclear medicine, globally?

In recent years, the nuclear medicine market has undergone many changes. The medical specialty, not well known to the general public, is gaining more...

News

Oncidium foundation welcomes it’s Turkish Ambassador, Mr. Hasan Ulaş Özcan

Welcome Mr. Hasan Ulaş Özcan as an Oncidium foundation Ambassador in Turkey. Our mission is to support & promote the development of Radiotheranostics globally....

News

Oncidium foundation is a corporate member of the SNMMI Value Initiative

The Oncidium foundation is a corporate member of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Value Initiative program to advance the crucial...

News

Joint Radionuclide Therapy-Immunotherapy Approach Effective in Prostate Cancer Model

Joint radionuclide therapy and immunotherapy approach. The combination shows promising therapeutic option for prostate cancer patients. Read full article >>

News

The Winter Newsletter is out!

Looking back at 2020 accomplishments, fundraising campaign, meeting the newcomers Ambassadors, focusing on the latest developments in the Radiotheranostics field and meeting Tom, neuroendocrine...

News

World Cancer Day 2021

Today, the Oncidium foundation unites its voice with the World Cancer Day! No matter who we are or where we live, this occasion is...

News

Hopeful 2021!

This year has shown us more than ever the importance of access, education & hope. We've adapted to new normal & witnessed once again the...

News

New Theranostic Approach reduces tumor volume and increases survival in NET’s study

Axis - Dec 16, 2020 According to new research published in the December issue of The Journal of Nuclear Medicine, the imaging agent 64Cu-CuSarTate produced high-quality...

News

Another achievement to bring Radiotheranostics forward

300 hospitals registered on the Oncidium foundation Map! Another achievement to bring Radiotheranostics forward and strive for access education and hope. Thank you to...

News

NET Patient Testimonial, how PRRT saved Tom’s life

Tom is a composer, pianist, audio producer and neuroendocrine tumor patient. When he was diagnosed with NET's, he didn't know that PRRT could save his life...

News

Diagnostic accuracy of 18 F-PSMA-1007-PET/CT imaging for prostate carcinoma

J. Nucl. Me. 2020 Aug 17 18F-PSMA-1007-PET/CT reliably detects malignant lymph nodes and has an exceptional specificity of >99% for nodal metastases. Congratulations for this...

Events

IPET 2020 – all you need to know about Theranostics

Event: IPET 2020, Beyond the visible - International Conference on Molecular Imaging and Clinical PET-CT in the Era of Theranostics Date: 24-26 November 2020 Don't miss...

News

Radiopharmaceuticals Emerging as New Cancer Therapy

National cancer Institute. October 26, 2020 The last years have seen an explosion of research and clinical trials testing new radiopharmaceuticals suggesting that targeting radiation...

News

October Rose – Breast Cancer Awareness Month

The Oncidium foundation wears the colors of October Rose. Breast Cancer is by far the most common cancer in women worldwide, both in developed...

Events

EANM ’20 – Let’s talk Radiotheranostics!

Event: EANM 2020 Annual Meeting - Virtual Edition Date: 22-30 October 2020 This year, the Oncidium foundation team looks forward to meeting you “virtually” at the EANM...

News

Nuclear Medicine and Molecular Imaging Week: October 4-10, 2020

October 4-10 2020 is nuclear medicine and molecular imaging week! A great initiative by Society of Nuclear Medicine and Molecular Imaging (SNMMI) to raise...

News

First clinical results for PSMA TAT using Ac-225-PSMA-I&T in advanced mCRPC patients

First clinical results for PSMA targeted alpha therapy using 225Ac-PSMA-I&T in advanced metastatic castration resistant prostate cancer patients: promising antitumor effect in advanced mCRPC...

News

IAEA activities on Cu-67, Re-186, Sc-47 Theranostic radionuclides and Radiopharmaceuticals

International Atomic Energy Agency (IAEA) activities on 67Cu, 186Re, 47Sc Theranostic radionuclides and Radiopharmaceuticals: Extraordinary results on the production, quality control and preclinical evaluation...

News

The Role of Ga-68-FAPI PET/CT for Patients with Malignancies of the Lower Gastrointestinal Tract: First Clinical Experience

The Role of 68Ga-FAPI PET/CT for Patients with Malignancies of the Lower Gastrointestinal Tract (LGT): First Clinical Experience seems to be a highly promising...

News

Cancer awareness month – September, don’t forget to remember

The month of September represents the prostate cancer, thyroid cancer, leukemia and lymphoma, and female cancer awareness month. Thus, an important way of supporting...

News

First patients dosed in clinical trial of novel lung and ovarian cancer theranostic

Telix Pharmaceuticals Limited announced that the first two patients have been dosed in a phase I study of the novel lung and ovarian cancer...

News

Sirtex Medical and China Grand Pharmaceutical announce landmark drug registration milestone

Sirtex Medical (“Sirtex”) is a leading manufacturer of targeted liver cancer therapies. It announced today that Sirtex and its shareholders have been issued a...

News

Efficacy and safety of 225 Ac-PSMA-617 TAT in Prostate Cancer

PubMed, July 23, 2020 Despite the success of several standards of care treatment options in metastatic castration-resistant prostate cancer (mCRPC), a significant number of patients...

News

Astatine is a chemistry puzzle that shows anticancer promise

c&en, chemical & engineering news, august 13, 2020. Astatine is the rarest naturally occurring element on Earth. It resists easy chemical classification. In reactions, it...

News

This is not a simple flower, this is an Oncidium

Ever wondered the meaning behind the name and logo of the Oncidium foundation? This is not a flower, this is an Oncidium. A kind of...

News

Webinar Theranostics and PET Imaging Diagnostics

Webinar Theranostics and PET Imaging Diagnostics by IBA RadioPharma Solutions Watch this instructive webinar on the use of PET radiopharmaceuticals in Theranostic applications....

News

Theranostics continue to gain momentum

Article by Richard Zimmermann, President & Founder of the Oncidium foundation. Radiotheranostics are molecules that can safely carry radioactive isotopes inside targeted human...

News

In memory of Sanjiv Sam Gambhir, a leader in the development of precision oncology

Molecular imaging pioneer Sanjiv Sam Gambhir, MD, PhD, passed away on Saturday, July 18, from cancer. He was 57. From the earliest days of his...

News

Another milestone for the Oncidium foundation

Another milestone for the Oncidium foundation: 200 registered hospitals and counting! Thank you to all the nuclear medicine experts that registered their treatment center using...

News

The Oncidium foundation supports the SVIMS

In India, the Sri Venkateswara Institute of Medical Sciences (SVIMS), is a University Hospital based in Tirupati. The city is home to most famous...

Events

SNMMI 2020 – Virtual Edition

Event: SNMMI 2020 Annual Meeting - Virtual Edition Date: 11-14 July 2020 The Oncidium foundation will be virtually attending and holding a booth. Find us under...

News

Atomic Nanogenerators in Targeted Alpha Therapy

Atomic in vivo nanogenerators such as actinium-225, thorium-227, and radium-223 are of increasing interest and importance in Targeted Alpha Therapy (TAT), in the treatment...

News

Postponing PRRT treatment during COVID 19

Postponing PRRT in Neuroendocrine tumors during COVID-19. What do you think? Check out the interesting responses of experts in the field. Read more >>

News

ProsTIC – The new Centre of Excellence

Congratulations Peter MacCallum Cancer Centre for the launch of The Prostate Theranostics & Imaging Centre of Excellence. ProsTIC will lead state-of-the-art research to deliver new...

News

Prostate Cancer Theranostics – An Overview

The implementation of theranostic approaches to characterize and personalize patient management is beginning to be realized for prostate cancer patients. This review article summarized...

News

TheraP Trial Design in Prostate Cancer

Interesting interview with Pr. Michael Hofman about TheraP Trial Design Evaluating 177Lu‐PSMA‐617 Theranostic Treatment vs Cabazitaxel in Progressive Metastatic Castration‐Resistant Prostate Cancer, where results are...

News

Oncidium Spring NEWSLETTER

Fresh news about Oncidium and Radiotheranostics, close up on Neuroendocrine Cancer UK, meet the Oncidium Ambassadors and much more! >> Discover the Newsletter

News

Covid19 – Stay safe

Today, we would like to raise awareness of a different nature, equally important. We hope your relatives and you are well and healthy. The...

News

The Oncidium foundation goes live !

After six months of hard labor, research and discussions, welcome to the Oncidium’s new website! The entire website has been face-lifted in a user-friendly way...

News

World Cancer Day

The 4th of February is the World Cancer Day. Let's increase opportunities to build global awareness and impact-driven action. Keep strong, keep believing, keep...

Events

EANM FOCUS MEETING – Theranostics for NET’s

Event: EANM FOCUS 3 - Molecular Imaging and Theranostics in Neuroendocrine tumours Date: Jan 30 - Feb 01, 2020 Location: Athens, Greece In-depth overview of the latest...

News

Radiolabeled PSMA PET for Renal Cancer

Promising results regarding the role of Radiolabeled PSMA PET as an imaging modality for the evaluation of widespread disease and response to target and...

News

How Radiotheranostics work?

Still wondering how Radiotheranostics work? Read this very interesting and accessible article by the International Atomic Energy Agency (IAEA):“It is a very efficient approach...

News

Strong potential of targeted α-therapy with 225Ac-PSMA-617

Targeted α-therapy with 225Ac-PSMA-617 although still preliminary, has demonstrated strong potential to significantly benefit advanced-stage prostate cancer patients. Dr. Machaba Michael Sathekge comments the...

News

Merry Christmas and Happy New Year

What a year! Looking back at 2019, we were able to start The Oncidium foundation activities, build a motivated team, meet wonderful dedicated people...

Oncidium foundation @OncidiumFoundat

10 hours ago
Inauguration of the Theragnostics Clinic at Stanford Healthcare. Watch till the end as we are offered a tour of the dedicated #theranostics space, notably with the visit of the infusion rooms. A great step towards enhancing access to #radiotheranostics technology. https://t.co/KKV1vwRKRo

View on Twitter

Oncidium foundation @OncidiumFoundat

7 days ago
NOBLE explained 👇
#NOBLERegistry #NobodyLeftBehind #iPSMA #SPECTimaging #prostatecancer #cancercare #precisiononcology #nuclearmedicine #radionuclides #seeittreatit
https://t.co/D788U7IXjT

View on Twitter

Noble Registry @NobleRegistry
NOBLE explained. The cause aims to enable access to #SPECTimaging in #prostatecancer #cancerdiagnosis, a more widely available and accessible technology compared with PET. NOBLE stands and aspires for NOBody LEft behind.
#NOBLERregistry #cancercare #iPSMA #enhancingaccess https://t.co/QY9NDTxIxr

Oncidium foundation @OncidiumFoundat

1 week ago
We may be waiting for the pandemic to be over, but cancer does not wait! Don't miss out on tomorrow's launch of the #TimeToActCancer Don’t let Covid-19 stop you from tackling cancer” campaign.
@EuropeanCancer
https://t.co/LvIv7WIiKH
#BeatingCancer #earlydetection #EUCancerPlan

View on Twitter

European Cancer Organisation @EuropeanCancer
Join the virtual launch of the #TimeToActCancer campaign 👇

'Don't let #Covid19 stop you from tackling #Cancer'

💡 New data
🗣 Resources in over 30 languages
🗓 Tuesday, 11 May @ 11:00-12:00 CEST

ℹ️ Register @ https://t.co/NfHhVM6tLZ

#BeatingCancer https://t.co/XpDtzuPXt6

Oncidium foundation @OncidiumFoundat

2 weeks ago
With increasing variety of #radiopharmaceuticals for #diagnostic or #therapeutic #nuclearmedicine as valuable diagnostic or treatment option, radiobiology plays an important role in supporting optimizations incl. safety & efficacy of #radionuclidetherapies
https://t.co/dXTWBh4ZB5

View on Twitter

LATEST NEWS AND EVENTS

CONNECT WITH US